GSK’s Stiefel begins Phase III trial of subcutaneous ofatumumab to treat pemphigus vulgaris
The global, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial will evaluate disease remission in these patients treated with subcutaneous ofatumumab as add-on treatment to oral steroids. In Pemphigus vulgaris,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.